Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zhang, Peng ^a   Guo, Zhiyong ^a   Wu, Ying ^a   Hu, Ronglin ^a   Du, Jun ^a   He, Xiaoshun ^a   Jiao, Xingyuan ^a   Zhu, Xiaofeng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CYCLIN D1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; TRICHOSTATIN A; VORINOSTAT; ANTINEOPLASTIC AGENT; BMI1 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; HISTONE; HYDROXAMIC ACID; MTOR PROTEIN, HUMAN; MYC PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; G1 PHASE CELL CYCLE CHECKPOINT; GALLBLADDER CANCER CELL LINE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GALLBLADDER NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; G1 PHASE CELL CYCLE CHECKPOINTS; GALLBLADDER NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; POLYCOMB REPRESSIVE COMPLEX 1; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84942432930     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136193     Document Type: Article

References (33)

1. Coburn NG, Cleary SP, Tan JC, Law CH. Surgery for gallbladder cancer: a population-based analysis. J Am Coll Surg 2008; 207: 371-382. doi: 10.1016/j.jamcollsurg.2008.02.031 PMID: 18722943
2. Zhang P, Jiang G, Gao J, Li L, Du J, Jiao X. SAHA down-regulates the expression of indoleamine 2,3-dioxygenase via inhibition of the JAK/STAT1 signaling pathway in gallbladder carcinoma cells. Oncol Rep 2013; 29: 269-275. doi: 10.3892/or.2012.2073 PMID: 23042548
3. Batra Y, Pal S, Dutta U, Desai P, Garg PK, Makharia G, et al. Gallbladder cancer in India: a dismal picture. J Gastroenterol Hepatol 2005; 20: 309-314. PMID: 15683437
4. Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 1996; 224: 639-646. PMID: 8916879
5. Butte JM, Matsuo K, Gönen M, D'Angelica MI, Waugh E, Allen PJ,et al. Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg 2011; 212: 50-61. doi: 10.1016/j.jamcollsurg.2010.09.009 PMID: 21075015
6. Czito BG, Hurwitz HI, Clough RW, Tyler DS, Morse MA, Clary BM, et al. Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys 2005; 62: 1030-1034. PMID: 15990005
7. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277: 8-21. doi: 10.1016/j.canlet.2008.08.016 PMID: 18824292
8. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23: 6693-6701. PMID: 15235588
9. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009; 280: 192-200. doi: 10.1016/j.canlet.2009.03.013 PMID: 19345475
10. Hahnen E, Hauke J, Tränkle C, Eyüpoglu IY, Wirth B, Blümcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 2008; 17: 169-184. doi: 10.1517/13543784.17.2.169 PMID: 18230051
11. Mwakwari SC, Patil V, Guerrant W, Oyelere AK. Macrocyclic histone deacetylase inhibitors. Curr Top Med Chem 2010; 10: 1423-1440. PMID: 20536416
12. Monneret C. Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs 2007; 18: 363-370. PMID: 17351388
13. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005; 23: 3971-3993. PMID: 15897549
14. Duvic M, Vu J. Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Biologics 2007; 1: 377-392. PMID: 19707308
15. Lin W, Jiang L, Chen Y, Li L, Du J, Jiao X. Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer. Cancer Lett 2012; 314: 127-136. doi: 10.1016/j.canlet.2011.09.004 PMID: 22071224
16. Zhang P, Jiang G, Gao J, Li L, Du J, Jiao X. SAHA down-regulates the expression of indoleamine 2, 3-dioxygenase via inhibition of the JAK/STAT1 signaling pathway in gallbladder carcinoma cells. Oncol Rep 2013; 29: 269-275. doi: 10.3892/or.2012.2073 PMID: 23042548
17. Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007; 110: 2667-2673. PMID: 17606765
18. Åndrén-Sandberg A, Deng Y. Aspects on gallbladder cancer in 2014. Curr Opin Gastroenterol 2014; 30: 326-331. doi: 10.1097/MOG.0000000000000068 PMID: 24686434
19. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552. PMID: 17694093
20. Chao OS, Goodman OB Jr. Synergistic Loss of Prostate Cancer Cell Viability by Co-inhibition of HDAC and PARP. Mol Cancer Res. 2014Aug 15. [Epub ahead of print]
21. Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, et al. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 2010; 101: 355-362. doi: 10.1111/j.1349-7006.2009.01387.x PMID: 19860841
22. Bajbouj K, Mawrin C, Hartig R, Schulze-Luehrmann J, Wilisch-Neumann A, Roessner A, et al. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J Neurooncol 2012; 107: 503-516. doi: 10.1007/s11060-011-0791-2 PMID: 22270849
23. Kitamura T, Connolly K, Ruffino L, Ajiki T, Lueckgen A, DiGiovanni J, et al. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol 2012; 57: 84-91. doi: 10.1016/j.jhep.2012.01.018 PMID: 22326466
24. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371-377. PMID: 12901945
25. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett 2012; 319: 1-7. doi: 10.1016/j.canlet.2012.01.005 PMID: 22261336
26. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16: 34-44. PMID: 20214616
27. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945. PMID: 15314020
28. Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004; 5: 519-523. PMID: 15193254
29. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 2008; 22: 2159-2168. doi: 10.1038/leu.2008.243 PMID: 18784743
30. Huang WJ, Lin CW, Lee CY, Chi LL, Chao YC, Wang HN, et al. NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. J Ethnopharmacol 2011; 136: 156-167. doi: 10.1016/j.jep.2011.04.034 PMID: 21530633
31. Erlich RB, Kherrouche Z, Rickwood D, Lasorsa E, Azabdaftari G, Godoy A, et al. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br J Cancer 2012; 106: 107-115. doi: 10.1038/bjc.2011.495 PMID: 22116303
32. Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, et al. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget 2013; 4: 2225-2236. PMID: 24163230
33. Gupta M, Ansell S, Novak A, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009; 114: 2926-2935. doi: 10.1182/blood-2009-05-220889 PMID: 19641186